V. Sloan

发表

Risk of QT prolongation and torsade de pointes associated with exposure to hydroxyzine: re‐evaluation of an established drug

J. Valentin, A. Schlit, A. Delaunois, 2017, Pharmacology research & perspectives.

Endorsement of the OMERACT core domain set for shared decision making interventions in rheumatology trials: Results from a multi-stepped consensus-building approach.

Linda C. Li, M. Suarez‐Almazor, P. Tugwell, 2021, Seminars in arthritis and rheumatism.

The OMERACT First-time Participant (“Newbie”) Program: Initial Assessment and Lessons Learned

J. Singh, Shawna Grosskleg, C. Pohl, 2015, The Journal of Rheumatology.

Preliminary evidence for a structural benefit of the new bisphosphonate zoledronic acid in early rheumatoid arthritis.

P. Emery, P. Conaghan, A. Grainger, 2006, Arthritis and rheumatism.

Rheumatology Common Toxicity Criteria (RCTC): An Update Reflecting Real-World Use

D. Furst, T. Woodworth, V. Sloan, 2019, Drug Safety.

Nonradiographic axial spondyloarthritis: expanding the spectrum of an old disease

M. Magrey, J. Stark, V. Sloan, 2022, Medicine.

A potential mechanism of cyclosporine-associated bone pain: comment on the radiologic vignette by Stone et al.

V. Sloan, E. O’neill, 1998, Arthritis and rheumatism.

Classification of reactive arthritides.

V. Sloan, D. R. Blumberg, 1998, Emerging infectious diseases.

Aspirin in In-Flight Emergencies

V. Sloan, 1998, Annals of Internal Medicine.

Standardizing Assessment and Reporting of Adverse Effects in Rheumatology Clinical Trials II: the Rheumatology Common Toxicity Criteria v.2.0

P. Brooks, J. Fries, D. Furst, 2007, The Journal of Rheumatology.

The Third Biennial 2018 OMERACT First-time Participant Program: A Qualitative and Quantitative Study

J. Singh, Shawna Grosskleg, V. Sloan, 2019, The Journal of Rheumatology.

The OMERACT First-time Participant Program: Fresh Eye from the New Guys

J. Singh, Shawna Grosskleg, C. Pohl, 2017, The Journal of Rheumatology.

MHC and infectious diseases.

V. Sloan, 1997, Emerging infectious diseases.

Apremilast: a novel PDE4 inhibitor in the treatment of autoimmune and inflammatory diseases

G. Schett, R. Stevens, P. Schafer, 2010, Therapeutic advances in musculoskeletal disease.

Apremilast : a novel PDE 4 inhibitor in the treatment of autoimmune and inflammatory diseases

G. Schett, R. Stevens, P. Schafer, 2010 .

Do Race and Ethnicity Play a Substantial Role in the Quality of Care That Patients Receive in the U.S. Health Care System

V. Sloan, 2009 .

Acute Epiglottitis due to Pasteurella multocida in an Adult without Animal Exposure

V. Sloan, 1997 .

Reiter syndrome following protracted symptoms of Cyclospora infection.

V. Sloan, 2001, Emerging infectious diseases.

Lumiracoxib in the treatment of osteoarthritis, rheumatoid arthritis and acute postoperative dental pain: results of three dose-response studies

T. Schnitzer, V. Sloan, J. Fricke, 2005, Current medical research and opinion.

Opioid Use in Patients with Ankylosing Spondylitis Is Common in the United States: Outcomes of a Retrospective Cohort Study

R. Suruki, J. Stark, V. Sloan, 2019, The Journal of Rheumatology.

A Benefit Risk Review of Pediatric Use of Hydrocodone/Chlorpheniramine, a Prescription Opioid Antitussive Agent for the Treatment of Cough

V. Sloan, J. Bentz, A. Jones, 2019, Drugs - Real World Outcomes.

Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a prospective randomized 13-week study versus placebo and celecoxib

J. Maldonado-Cocco, R. Fleischmann, V. Sloan, 2006, Clinical Rheumatology.

Efficacy and tolerability of lumiracoxib 100 mg once daily in knee osteoarthritis: a 13-week, randomized, double-blind study vs. placebo and celecoxib

S. Litschig, V. Sloan, M. Brzosko, 2005, Current medical research and opinion.

Efficacy and tolerability of lumiracoxib in the treatment of osteoarthritis of the knee: a 13-week, randomized, double-blind comparison with celecoxib and placebo.

A. Beaulieu, V. Sloan, E. Sheldon, 2005, Clinical therapeutics.

Cardiovascular safety of lumiracoxib: a meta-analysis of all randomized controlled trials > or =1 week and up to 1 year in duration of patients with osteoarthritis and rheumatoid arthritis.

J. Orloff, M. Olson, V. Sloan, 2005, Clinical therapeutics.

Identifying Possible Outcome Domains from Existing Outcome Measures to Inform an OMERACT Core Domain Set for Safety in Rheumatology Trials

M. Suarez‐Almazor, P. Tugwell, N. Goel, 2019, The Journal of Rheumatology.

Efficacy, safety and tolerability of lumiracoxib in patients with rheumatoid arthritis

P. Geusens, P. Richardson, R. Alten, 2004, International journal of clinical practice.

Efficacy and safety of four doses of lumiracoxib versus diclofenac in patients with knee or hip primary osteoarthritis: a phase II, four-week, multicenter, randomized, double-blind, placebo-controlled trial.

T. Schnitzer, P. Geusens, P. Hasler, 2004, Arthritis and rheumatism.

Improving domain definition and outcome instrument selection: Lessons learned for OMERACT from imaging.

Win Min Oo, M. D. de Wit, D. Beaton, 2021, Seminars in arthritis and rheumatism.

PRTX-100 Inhibits Platelet Phagocytosis In Vitro.

V. Sloan, S. Siddiqui, C. Herrem, 2006 .

The Content of Their Character

V. Sloan, 2008, Annals of Internal Medicine.

Sexual behavior in Peace Corps volunteers.

V. Sloan, 1992, Archives of internal medicine.

Efficacy of Lumiracoxib in Osteoarthritis: A Review of Nine Studies

F. Berenbaum, J. Grifka, V. Sloan, 2005, The Journal of international medical research.